Leah Lawrence

Researchers identified 13,419 COVID-19 deaths with cancer as a contributing cause and 3142 cancer deaths with COVID-19 as a contributing cause.

Researchers devised a guide to help clinicians determine if regional differences in clinical trial outcomes are clinically meaningful.

A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.

Grouping Asian and Pacific Islander patients together may hide disparities in cancer outcomes between these groups, according to researchers.

Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.

Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.

Among patients with HR+/HER2- breast cancer, BRCA1/2 carriers were twice as likely as non-carriers to receive platinum chemotherapy.

At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.

The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.

There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.